| Pharmaceutical Formulations | Finished Dosage Forms across acute, chronic, sub-chronic and specialty therapeutic areas. | Strong domestic marketing network with leadership in stomatology; FDA and MHRA compliant manufacturing facilities. | B2B focus serving medical institutions, healthcare providers, and pharmacies. | Specialty therapeutic divisions and new products in lifestyle segments. | 1300 | 78 | Sales of pharmaceutical products to hospitals, clinics, and distributors. | Direct sales and distribution with negotiated contracts and standard pricing. | New product launches, expansion in cardio-vascular and diabetic segments, enriched marketing network. | Naricover, Dropizin Syrup, Methycal 60 K, Rexidin SRS, Noxa, Subitral |
| Active Pharmaceutical Ingredients (APIs) | Manufacturing and sale of APIs supporting formulations internally and externally. | Process patents and regulatory approvals provide competitive edge. | B2B focus with pharmaceutical companies and internal formulations division. | Proprietary APIs with process patents yielding higher margins. | 250 | 15 | Contract manufacturing and direct sales of APIs. | Contract and direct sales pricing. | Patented manufacturing processes and increased internal consumption. | |
| Contract Research and Clinical Research | Clinical trials, bioequivalence studies, and research services via owned CRO facilities. | UK MHRA GCP and GLP accreditation; US FDA approvals enhance credibility and clientele. | Pharmaceutical companies requiring clinical and bioequivalence studies. | Bioequivalence and specialty clinical trial services. | 115 | 7 | Service fees from clinical research contracts and studies. | Project-based fees and contracts. | In-house clinical research reduces outsourcing, accelerates R&D timelines. | |
